Penn Davis Mcfarland 13F: Cuts ROIV Stake by $2.1M

Penn Davis McFarland reduced its holdings in Roivant Sciences Ltd. ROIV during the period, according to a Form 13F filing with the SEC on October 23, 2026. The firm trimmed its position by 56,846 shares, marking a 3.5% decrease from the previous quarter.

ROIV Roivant Sciences Ltd.

$37.45 ▲ +70.77% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Penn Davis McFarland's Roivant Sciences Position

Penn Davis McFarland ended the period with 1,523,345 shares of Roivant Sciences Ltd., down from the 1,580,191 shares held prior to the filing. The remaining stake carried a reported value of $55,708,727 as of the filing date.

Other Institutional Activity in Roivant Sciences

Other large investors adjusted their positions in the biopharmaceutical company during recent periods. QVT Financial LP held 23,723,074 shares worth $865,655,010 after trimming its stake by 1,439,287 shares or 5.7%. Farallon Capital Management LLC grew its holdings by 4,634,220 shares to end with 14,309,000 shares valued at $522,135,434, a 47.9% increase. Meanwhile, IFM Investors picked up 128,826 shares for a total holding of 128,826 shares worth $4,711,167.

Roivant Sciences Ltd. Stock Down 0.8%

Roivant Sciences Ltd. shares closed at $36.49 on October 23, 2026, and recently traded at that same level. The stock sits below its 52-week high of $42.50 and far above its 52-week low of $17.89. Shares rest below their 50-day moving average of $36.64 while remaining above their 200-day moving average of $31.07.

Recent Earnings

Roivant Sciences Ltd. posted trailing twelve month revenue of $7,532,000 alongside a trailing twelve month earnings per share of -$0.54. The clinical-stage biopharmaceutical firm recorded a year-over-year revenue decline of 33.5% with a return on equity of -8.5%. The company is scheduled to share its next financial results on November 9, 2026.

Insider Buying and Selling at Roivant Sciences Ltd.

Company insiders executed several transactions prior to the filing. Eric Venker, President and CEO of Immunovant, sold 200,000 shares on October 20, 2026, at an average price of $35.11 under a planned schedule. Other historical transactions included sales by Keith Manchester and QVT Financial LP.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. HC Wainwright & Co., TD Cowen, and Guggenheim maintained buy ratings with increased price targets, while Stifel initiated coverage with a buy rating. Wolfe Research downgraded the stock to a peer perform rating in October.

About Roivant Sciences

Roivant Sciences Ltd. is a London-based biopharmaceutical firm focused on developing and commercializing medicines and health technologies through targeted subsidiary companies. The company works across multiple therapeutic areas to bring clinical treatments forward.

Bottom Line

Institutional adjustments and insider transactions continue to shape trading around Roivant Sciences Ltd. Investors will look toward the upcoming earnings release on November 9, 2026, for further updates on the company's clinical pipeline and financial position.